Medical/Pharmaceuticals

GILEAD SCIENCES AWARDS OVER US$1.5 MILLION TO STRENGTHEN SUPPORT FOR COMMUNITY-LED HIV PROJECTS IN ASIA PACIFIC

–2023 Gilead Asia Pacific Rainbow Grant Funding Will Support 40 Projects In 2024-2025 To Reduce HIV Stigma And Improve Equity Across Asia Pacific – – Since 2018, The Gilead Asia Pacific Rainbow Grant Has Awarded Close To US$6 Million To 144 Community-Based Projects In The Region, Supporting 130 00...

2023-11-29 11:00 1608

"Anti-Choke Mug" - Chula Innovation for Neuro Patients to Drink Water Confidently

BANGKOK, Nov. 29, 2023 /PRNewswire/ -- Chula  Medicine has designed an anti-choke mug with calculated angle, amount, and time of water flow from the mug to the patient's lips hoping to reduce choking that may lead to lung infection, bring peace of mind to caregivers, ...

2023-11-29 10:00 1289

VISTA Eye Specialist Unveils Innovative Solution for Reading Problems

PETALING JAYA, Malaysia, Nov. 29, 2023 /PRNewswire/ -- VISTA Eye Specialist (VISTA) proudly introduces the groundbreaking EVO Viva Implantable Collamer Lens (Viva) to address the dual challenge of short-sightedness and reading problems (presbyopia) among patients aged above 40. This cutting-edge ...

2023-11-29 08:00 1389

Kailo Medical Presents: KailoFlow - Elevating the Generative Reporting Experience to the Web

CHICAGO, Nov. 29, 2023 /PRNewswire/ -- Kailo Medical, a recognized leader in medical software and services, proudly announces the launch ofKailoFlow, the web-based evolution of the premier structured reporting platform,SonoReview. Marrying progress, innovation, and accessibility, KailoFlow is the...

2023-11-29 07:11 953

Wonder Tech's Breakthrough in Language Agnostic Voice AI to Bring Scalable Depression Screening to One Billion People Globally

SINGAPORE, Nov. 28, 2023 /PRNewswire/ -- Wonder Technologies PTE. LTD ("Wonder Tech" or "the Company"), a leading AI-driven mental health solutions company based inSingapore, has reached a breakthrough in its acoustics-based AI for depression screening. The AI model, which identifies depression t...

2023-11-29 00:00 1571

Rhino Rescue Expands Horizons at Medica 2023, Exploring New Opportunities in the European Market

DÜSSELDORF, Germany, Nov. 28, 2023 /PRNewswire/ -- Rhino Rescue made a strong appearance at Medica inGermany, showcasing the comprehensive range of its latest technologies and products. During the event, more than 20 companies expressed their intention to partner with Rhino Rescue, thereby expand...

2023-11-28 23:00 1155

Dr. Liu Jian, President of Medicilon Drug Discovery Division, wins the Thomas Alva Edison Patent Award

BOSTON, Nov. 28, 2023 /PRNewswire/ -- Dr. Liu Jian, President of the Drug Discovery Division at Medicilon, has been awarded the Thomas Alva Edison Patent Award for 2023 from the New Jersey Research and Development Committee. This recognition stems from his innovative patent on the PCSK9 inhibitor...

2023-11-28 21:30 1032

Akeso Launches Construction of Shanghai Global R&D Center to Accelerate Its Innovation Globalization Strategy

HONG KONG, Nov. 28, 2023 /PRNewswire/ -- The groundbreaking ceremony for Akeso (9926.HK)  Shanghai Global R&D Center was successfully held at the Zhangjiang headquarters park inShanghai. The establishment of the Akeso Global R&D Center signifies a crucial step in Akeso's innovative globalization ...

2023-11-28 21:00 1853

Novavax's Updated Protein-based COVID-19 Vaccine Now an Option for All 194 Member States of the World Health Organization

GAITHERSBURG, Md., Nov. 28, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that Nuvaxovid™ XBB.1.5 COVID-19 Vaccine (NVX-CoV2601) has been granted Emergency Use Listing (EUL) by the World Health Or...

2023-11-28 19:00 1622

JOGO HEALTH (INDIA) GRANTED WORLD'S FIRST JOINT COMMISSION INTERNATIONAL(JCI) ACCREDITATION FOR A DIGITAL CLINIC

* Chicago based Joint Commission helps healthcare organizations improve clinical and operational processes and build staff competencies and knowledge of leading practices. * More than 22,000 US health care organizations are accredited by Joint Commission and a majority of US state government...

2023-11-28 16:01 1297

RemeGen Announces Publication of Results from Two Phase II Studies for Disitamab Vedotin in Latest Issue of Journal of Clinical Oncology (JCO)

YANTAI, China, Nov. 28, 2023 /PRNewswire/ -- RemeGen Co. Ltd. ("RemeGen" or "the Company") (9995.HK, SHA: 688331), a commercial-stage biotechnology company, today announced its two Phase II, open-label, multicenter, single-arm studies for Disitamab Vedotin (RC48-C005 an...

2023-11-28 09:48 1827

Daewoong Pharmaceutical Received GMP Certification from Brazilian ANVISA

SEOUL, South Korea, Nov. 28, 2023 /PRNewswire/ -- Daewoong Pharmaceutical is pleased to announce that its Osong factory in Korea achieved Good Manufacturing Practice (GMP) certification from the Regulatory Authority ofBrazil, ANVISA. Daewoong Pharmaceutical, represented by CEO Seng-ho Jeon and ...

2023-11-28 08:00 1249

AI-Powered TIL Analysis by Lunit Unveils Prognostic Insights for Colon Cancer - published in npj Precision Oncology

* AI-powered spatial analysis of tumor-infiltrating lymphocytes using Lunit SCOPE IO provides accurate prognosis prediction in stage II–III colon cancer SEOUL, South Korea, Nov. 27, 2023 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and...

2023-11-27 22:05 1119

Cadonilimab (PD-1/CTLA-4 Bispecific Antibody) Met Primary Endpoint of Progression-Free Survival in Phase III Trial for First-Line Treatment of Recurrent/Metastatic Cervical Cancer in All-Comer Patients

HONG KONG, Nov. 27, 2023 /PRNewswire/ -- Akeso (9926. HK) has announced that the AK104-303 Phase III trial, which investigated cadonilimab (Akeso's PD-1/CTLA-4 bispecific antibody) combined with platinum-based chemotherapy +/- bevacizumab, has met one of its primary endpoints of progression-fre...

2023-11-27 21:30 1208

XtalPi and HKU's Advanced Biomedical Instrumentation Centre Sign MoU to Accelerate Deep Tech Commercialization

CAMBRIDGE, Mass., Nov. 27, 2023 /PRNewswire/ -- XtalPi Inc. (XtalPi) and the Advanced Biomedical Instrumentation Centre (ABIC or the Centre) at the University of Hong Kong (HKU) have entered a memorandum of understanding (MoU) that outlines a roadmap for scientific collaboration and commercializat...

2023-11-27 21:20 1551

"Anti-Choke Mug" - Chula Innovation for Neuro Patients to Drink Water Confidently

BANGKOK, Thailand, Nov. 27, 2023 /PRNewswire/ -- Chula  Medicine designed an anti-choke mug  with calculated angle, amount, and time of water flow from the mug to the patient's lips hoping to reduce choking that may lead ...

2023-11-27 12:23 1658

Fovia Ai to Showcase Optimized AI Visualization at IAIP Exhibit, RSNA 2023

Fovia Ai Provides Efficient AI Results in One Unified Viewer CHICAGO, Nov. 26, 2023 /PRNewswire/ -- Fovia Ai, Inc., a subsidiary of Fovia, Inc., a world leader in advanced visualization for over two decades and a preeminent provider of zero-footprint, cloud-based imaging SDKs, today announced th...

2023-11-26 22:00 1710

Vieworks Showcases X-ray Imaging Excellence: RSNA 2023 Spotlight

ANYANG, South Korea, Nov. 25, 2023 /PRNewswire/ -- Vieworks, a renowned digital x-ray imaging solutions provider, is set to unveil pioneering advancements at RSNA 2023 inChicago (Booth 1723, November 26th-29th). Building on the success of prior RSNA exhibitions, Vieworks will present its comprehe...

2023-11-25 04:00 3017

DxVx, plans to make a license-in agreement of OVM-200 and conduct clinical trials in Asia

- Final stage in licensing OVM-200 from Oxford Vacmedix in the UK - DxVx plans to proceed its own clinical trials in Asia, including Korea and China  SEOUL, South Korea, Nov. 24, 2023 /PRNewswire/ -- DxVx announces today that it will conduct its own clinical trials of OVM-200, an anti-cancer vacc...

2023-11-24 22:00 3055

Ascentage Pharma Hosts Ceremony Marking the Launch of Olverembatinib in Newly Approved Indication and the Dispatch of First Batch for the New Indication

SUZHOU, China, and ROCKVILLE, Md., Nov. 24, 2023 /PRNewswire/ -- 23 Nov, 2023, on the second anniversary of the initial approval for olverembatinib, Ascentage Pharma hosted a ceremony in Suzhou,China, marking the launch of olverembatinib in a newly approved indication and the dispatch of the firs...

2023-11-24 19:57 2094
1 ... 47484950515253 ... 577